Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 40366350 | 2025 | A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies. Molecular cancer therapeutics Likely relevant The study tests the bispecific antibody PF-07260437, palbociclib, fulvestrant, and anti-PD-1 in breast cancer cell lines and animal models, measuring T-cell numbers, activation, and intratumoral CD8 T cells. | PF-07260437; palbociclib; fulvestrant; anti-PD-1 | Mixed | breast cancer | PF-07260437 0/0/0; palbociclib 0/2/0; fulvestrant 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 40369063 | 2025 | STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity. Nature Likely relevant The study experimentally tests STAT3 PROTAC degraders (SD-36 and SD-2301) in mice and measures effects on dendritic cell function and T cell immunity. | SD-36; SD-2301 | Animal | advanced tumours | SD-36 0/0/0; SD-2301 0/0/0 | Awaiting curator check |
| 40424822 | 2025 | Co-targeting the CD73-adenosinergic axis enhances the anti-tumor efficacy of anti-PD-L1 immunotherapy in bladder cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Likely relevant The study tests CD39/CD73 inhibitors and anti-PD-L1 immunotherapy in a murine bladder cancer model and measures circulating T cells and the neutrophil-to-lymphocyte ratio. | anti-PD-L1; CD39 inhibitors; CD73 inhibitors | Animal | bladder cancer | anti-PD-L1 0/15/0; CD39 inhibitors 0/0/0; CD73 inhibitors 0/0/0 | Awaiting curator check |
| 40433989 | 2025 | Exosomal CMTM4 Induces Immunosuppressive Macrophages to Promote Ovarian Cancer Progression and Attenuate Anti-PD-1 Immunotherapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant The study evaluates eltrombopag as a CMTM4 inhibitor combined with PD-1 blockade in vivo, assessing macrophage polarization and immune microenvironment changes. | eltrombopag; anti-PD-1 | Animal | ovarian cancer | eltrombopag 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 40439109 | 2025 | Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Cancer communications (London, England) Likely relevant The study tests anti-PD-1 antibodies and lipid inhibitors in vivo and evaluates their effects on immune evasion, PD-L1 levels, and the tumor microenvironment. | anti-PD-1; PCSK9-neutralizing antibodies; lipid inhibitors | Mixed | pancreatic ductal adenocarcinoma | anti-PD-1 14/36/0; PCSK9-neutralizing antibodies 0/0/0; lipid inhibitors 0/0/0 | Awaiting curator check |
| 40439143 | 2025 | Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma. Oncoimmunology Likely relevant The study tests anti-PD-L1 and anti-VEGFR2 in a mouse model of pleural mesothelioma and analyzes tumor-infiltrating immune cells and T cell exhaustion. | anti-PD-L1; anti-VEGFR2 | Animal | pleural mesothelioma | anti-PD-L1 0/15/0; anti-VEGFR2 0/0/0 | Awaiting curator check |
| 40461940 | 2025 | Reprogramming Tumor-Associated Macrophage by Ornithine Decarboxylase Inhibitor and Immune Checkpoint for Orthotopic Glioblastoma Photothermal Immunotherapy. ACS applied materials & interfaces Likely relevant The study tests DFMO, aPD-L1, and ICG in an orthotopic glioma mouse model and measures TAM repolarization, phagocytic activity, and immunogenic cell death. | difluoromethylornithine; aPD-L1; Indocyanine Green | Animal | glioblastoma | difluoromethylornithine 0/0/0; aPD-L1 0/0/0; Indocyanine Green 1/2/0 | Awaiting curator check |
| 40465005 | 2025 | Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models. Cancer immunology, immunotherapy : CII Likely relevant The study tests an oncolytic adenovirus combined with chemotherapy and immune checkpoint inhibitors in ex vivo tumor samples and hamster models, measuring PD-L1, cytokines, and CD8+ T cell expansion. | Ad5/3-E2F-d24-vIL2; chemotherapy; immune checkpoint inhibitor | Mixed | pancreatic ductal adenocarcinoma | Ad5/3-E2F-d24-vIL2 0/0/0; chemotherapy 2/0/3; immune checkpoint inhibitor 0/0/0 | Awaiting curator check |
| 40522918 | 2025 | Estrogens determine the efficacy of cancer immunotherapy in obese males with melanoma. JCI insight Likely relevant The study investigates the impact of obesity, estrogen levels, and letrozole administration on anti-PD-1 efficacy and CD8+ T cell/dendritic cell functions in mice and human melanoma patients. | immune checkpoint inhibitors (ICI); anti-PD-1; letrozole | Mixed | melanoma | immune checkpoint inhibitors (ICI) 0/0/0; anti-PD-1 14/36/0; letrozole 0/0/0 | Awaiting curator check |
| 40591413 | 2025 | Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response. The Journal of clinical investigation Likely relevant The study investigates LAIR1 inhibition via antibody blockade and CAR T cells in tumor models and measures changes in CD8 memory T cells and macrophage phenotypes. | anti-Lair1 antibody; 3-in-1 CAR T cells | Animal | cancer (tumor models) | anti-Lair1 antibody 0/0/0; 3-in-1 CAR T cells 0/0/0 | Awaiting curator check |
| 40605065 | 2025 | Elucidating the role of N-myristoylation in the excessive membrane localization of PD-L1 in hypoxic cancers and developing a novel NMT1 inhibitor for combination with immune checkpoint blockade therapy. Journal of experimental & clinical cancer research : CR Likely relevant The study tests an anti-PD-1 antibody combined with the NMT1 inhibitor PCLX-001 in HNSCC xenograft mice, measuring PD-L1 membrane localization and immune suppression. | anti-PD-1 antibody; PCLX-001 | Animal | head and neck squamous cell carcinoma | anti-PD-1 antibody 0/2/0; PCLX-001 0/0/0 | Awaiting curator check |
| 40610636 | 2025 | Impaired autophagy by cepharanthine induces immunogenic cell death and enhances anti-PD-1 response in MSS-type colorectal cancer. Oncogene Likely relevant Examines the immunogenic cell death and immune responses induced by cepharanthine and anti-PD-1 therapy in CRC models. | cepharanthine; anti-PD-1 | Animal | colorectal cancer | cepharanthine 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 40646287 | 2025 | Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy. British journal of cancer Likely relevant The study experimentally tests the ribosome biogenesis inhibitor CX-5461 in in vivo models and human samples, measuring its immunomodulatory effects on immune cell cytotoxicity, macrophage reprogramming, and immune checkpoint expression. | CX-5461 | Mixed | cancer | CX-5461 2/0/0 | Awaiting curator check |
| 40665335 | 2025 | Tumor-intrinsic ENO1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD-L1 immunotherapy in bladder cancer. Journal of experimental & clinical cancer research : CR Likely relevant The study tests ENO1 knockdown/inhibition alongside anti-PD-L1 immunotherapy in models and clinical samples, measuring CD8+ T cell infiltration and macrophage polarization. | anti-PD-L1 | Mixed | bladder cancer | anti-PD-L1 0/15/0 | Awaiting curator check |
| 40702186 | 2025 | NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature Likely relevant The study tests a small molecule NNMT inhibitor in murine models and measures its impact on MDSCs and CD8+ T cell activation. | NNMT inhibitor | Animal | ovarian cancer, breast cancer, colon tumour | NNMT inhibitor 0/0/0 | Awaiting curator check |
| 40745160 | 2025 | Mogat1 drives metabolic adaptations to evade immune surveillance. Nature communications Likely relevant The study evaluates the effect of PD-1 blockade in combination with genetic inhibition of Mogat1 in tumor-bearing mice and measures T-cell infiltration. | PD-1 blockade | Animal | solid tumors | PD-1 blockade 0/0/0 | Awaiting curator check |
| 40774370 | 2025 | Nanoparticle-induced excessive mitophagy combined with immune checkpoint blockade for enhanced cancer immunotherapy. Acta biomaterialia Likely relevant The study uses a therapeutic nanoplatform to induce mitophagy and silence PD-L1 in breast cancer models, evaluating CD8+ T cell activity and immunosuppressive cell infiltration. | CCCP; siRNA against PD-L1 | Animal | breast cancer | CCCP 0/0/0; siRNA against PD-L1 0/0/0 | Awaiting curator check |
| 40801643 | 2025 | Residual Tumor Resection After Anti-PD-1 Therapy: A Promising Treatment Strategy for Overcoming Immune Evasive Phenotype Induced by Anti-PD-1 Therapy in Gastric Cancer. Cells Likely relevant The study evaluates surgical resection after chemotherapy or anti-PD-1 therapy in patients with gastric cancer and analyzes the immune status (HLA class I and MHC class II expression) of the tumor microenvironment. | anti-PD-1 therapy; chemotherapy | Patient | gastric/gastroesophageal junction cancer | anti-PD-1 therapy 0/0/0; chemotherapy 2/0/3 | Awaiting curator check |
| 40810617 | 2025 | Nanozyme-Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder-Metastasized Tumors. Advanced materials (Deerfield Beach, Fla.) Likely relevant The study tests a nanozyme-based platform combined with PD-L1 nanobody in a bladder cancer model and measures immunogenic cell death and immune activation. | RePd nanozyme; PD-L1 nanobody; immune-checkpoint inhibitors | Animal | bladder cancer | RePd nanozyme 0/0/0; PD-L1 nanobody 0/0/0; immune-checkpoint inhibitors 0/0/0 | Awaiting curator check |
| 40816293 | 2025 | DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. Cancer cell Likely relevant Tests DNASE1L3 injection alongside anti-PD-(L)1 therapy in murine tumor models, measuring CD8+ T cell infiltration and exhaustion. | anti-PD-(L)1 | Animal | cancer (general) | anti-PD-(L)1 0/0/0 | Awaiting curator check |
| 40828008 | 2025 | Programmable immunoprobiotics orchestrate antitumor immune response with Pin1 inhibition for pancreatic cancer treatment. Proceedings of the National Academy of Sciences of the United States of America Likely relevant The study tests a Pin1 inhibitor and anti-PD-L1 delivery system in orthotopic mouse models and assesses immune cell infiltration and CD8+ T cell immunity. | API-1; anti-PD-L1 nanobodies | Animal | pancreatic ductal adenocarcinoma | API-1 0/0/0; anti-PD-L1 nanobodies 0/0/0 | Awaiting curator check |
| 40851062 | 2025 | The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy. BMC cancer Likely relevant The study investigates the association of immune cell infiltrates (CD4, CD8, CD68, FoxP3, PD-L1) with patient response to anti-PD-1 immunotherapy (sintilimab) combined with platinum-based chemotherapy. | sintilimab; platinum-based chemotherapy | Patient | Gastric or Gastroesophageal Junction (G/GEJ) cancer | sintilimab 0/0/1; platinum-based chemotherapy 0/0/0 | Awaiting curator check |
| 40886775 | 2025 | Polymeric-based neoantigen nanovaccine synergizes with PD-1/PD-L1 modulators, reprogramming the melanoma microenvironment. Journal of controlled release : official journal of the Controlled Release Society Likely relevant The study experimentally tests a polymeric nanovaccine combined with PD-1/PD-L1 pathway modulators in a mouse melanoma model and measures T-cell activation, infiltration, and immunosuppressive cell populations. | mannose-grafted PLGA nanovaccine; anti-PD-L1 monoclonal antibody; SM56 | Animal | melanoma | mannose-grafted PLGA nanovaccine 0/0/0; anti-PD-L1 monoclonal antibody 0/0/0; SM56 0/0/0 | Awaiting curator check |
| 40907793 | 2025 | Polymer-based chemo-immunotherapy: Combining immunogenic cell death induction and PD-L1 blockade enhances antitumor immunity in melanoma. Journal of controlled release : official journal of the Controlled Release Society Likely relevant Tests a polymer-based chemo-immunotherapy conjugate (KT-1/epirubicin and MPPA) in melanoma models and measures multiple immune readouts. | KT-1; MPPA; epirubicin | Animal | melanoma | KT-1 0/0/0; MPPA 0/0/0; epirubicin 0/0/0 | Awaiting curator check |
| 40909279 | 2025 | SLAMF7 (CD319) enhances cytotoxic T-cell differentiation and sensitizes CD8+ T cells to immune checkpoint blockade. Frontiers in immunology Likely relevant The study tests the combination of SLAMF7 activation with PD-1/PD-L1 immune checkpoint blockade in human T cells, measuring cytokine release and cytotoxic potential. | PD-1/PD-L1 immune checkpoint blockade | Cell line | head and neck squamous cell carcinoma (HNSCC) | PD-1/PD-L1 immune checkpoint blockade 0/0/0 | Awaiting curator check |